Kaplan–Meier curves for anti-topo-I and anti-AT₁R reactivity before aSCT in relation to the outcome after aSCT. Anti-topo-I- (a) and anti-AT₁R antibody reactivity (b) measured by ELISA and functional anti-AT₁R antibody reactivity measured by luminometric assay (c) in SSc-patients with good prognosis (group 1) and those with relapse or no response (group 2) after aSCT. For anti-topo-I antibodies (a), area under the curves (AUC) were significantly different comparing group 1 and group 2 patients; i.e. a strong anti-topo-I reactivity at tp0 was associated with a high probability to non-response or relapse after aSCT. For anti-AT₁R antibodies (b) AUC did not differ significantly between both groups. Presence of stimulatory anti-AT₁R antibodies (c) was associated with significantly higher probability to have a good prognosis after aSCT